Sumitomo Mitsui Trust Group Inc. Sells 19,865 Shares of Solventum Corporation $SOLV

Sumitomo Mitsui Trust Group Inc. trimmed its position in Solventum Corporation (NYSE:SOLV) by 6.2% during the fourth quarter, Holdings Channel reports. The institutional investor owned 299,042 shares of the company’s stock after selling 19,865 shares during the quarter. Sumitomo Mitsui Trust Group Inc.’s holdings in Solventum were worth $23,696,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of SOLV. Independent Franchise Partners LLP boosted its position in Solventum by 27.2% in the 3rd quarter. Independent Franchise Partners LLP now owns 12,899,240 shares of the company’s stock valued at $941,645,000 after buying an additional 2,758,174 shares during the last quarter. Boston Partners boosted its position in Solventum by 26.1% in the 3rd quarter. Boston Partners now owns 4,630,300 shares of the company’s stock valued at $338,006,000 after buying an additional 959,543 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares during the last quarter. Balyasny Asset Management L.P. bought a new position in shares of Solventum in the 3rd quarter worth $42,393,000. Finally, Pzena Investment Management LLC bought a new position in shares of Solventum in the 3rd quarter worth $31,701,000.

Insider Activity

In other news, Director Amy Mcbride Wendell purchased 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The shares were purchased at an average price of $68.03 per share, with a total value of $100,344.25. Following the purchase, the director directly owned 5,039 shares of the company’s stock, valued at $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.24% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Wells Fargo & Company upgraded Solventum to a “hold” rating in a research report on Wednesday, March 18th. BTIG Research restated a “buy” rating and issued a $100.00 price target on shares of Solventum in a research report on Friday, February 27th. KeyCorp raised their price target on Solventum from $97.00 to $99.00 and gave the stock an “overweight” rating in a research report on Friday, February 27th. Weiss Ratings restated a “hold (c)” rating on shares of Solventum in a research report on Tuesday, January 27th. Finally, Rothschild & Co Redburn assumed coverage on Solventum in a research report on Tuesday, March 24th. They issued a “sell” rating and a $60.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $90.64.

Solventum Stock Performance

Shares of Solventum stock opened at $68.82 on Friday. The company has a market capitalization of $11.93 billion, a PE ratio of 7.76, a PEG ratio of 1.13 and a beta of 0.71. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $88.20. The company has a current ratio of 1.23, a quick ratio of 0.89 and a debt-to-equity ratio of 1.00. The stock’s fifty day simple moving average is $69.59 and its 200 day simple moving average is $74.76.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $1.57 EPS for the quarter, topping the consensus estimate of $1.50 by $0.07. The business had revenue of $2 billion for the quarter, compared to the consensus estimate of $1.96 billion. Solventum had a return on equity of 25.26% and a net margin of 18.69%.The firm’s revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.41 EPS. Solventum has set its FY 2026 guidance at 6.400-6.600 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.